Management expects GeneDx (WGS) to deliver full year 2025: Revenues between $350 and $360 million and growth in exome/genome volume and revenue of at least 30%; Adjusted gross margins between 65%-67%; and Profitability with adjusted net income each quarter and for full year 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- WGS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- GeneDx selloff after short report ‘appears overdone,’ says Wells Fargo
- BTIG says GeneDx short report creates buying opportunity
- GeneDx Holdings: Overcoming Allegations with Strategic Reforms and Growth Potential
- GeneDx short report ‘misguided,’ buy on weakness, says Craig-Hallum